| DIRECT COMPETITOR COMPARISON | |
| ALXA | APPA | ARDM.OB | Pvt1 | Industry | | Market Cap: | 112.01M | 35.55M | 14.74M | N/A | 176.32M | | Employees: | 111 | 32 | 38 | 351 | 94 | | Qtrly Rev Growth (yoy): | N/A | 1,645.30% | 2,378.70% | N/A | 22.40% | | Revenue (ttm): | 9.93M | 1.16M | 4.88M | 1.10M1 | 42.63M | | Gross Margin (ttm): | 100.00% | 100.00% | 63.53% | N/A | 56.06% | | EBITDA (ttm): | -47.56M | -11.60M | -12.40M | N/A | -7.66M | | Oper Margins (ttm): | -528.95% | -1,032.16% | -278.15% | N/A | 2.25% | | Net Income (ttm): | -98.90M | -11.98M | -15.73M | -43.50M1 | N/A | | EPS (ttm): | -2.909 | -0.389 | -0.194 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | N/A | N/A | 16.69 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.01 | | P/S (ttm): | 11.49 | 30.55 | 3.14 | N/A | 4.17 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.49 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | APPA | | AP PHARMA INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
Tue, Nov 24 -
EDGAR Online | | • | APPA | | A.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing Requirements
Mon, Nov 23 -
Business Wire | | • | APPA | | AP PHARMA INC /DE/ Financials
Fri, Nov 20 -
EDGAR Online Financials | | • | APPA | | AP PHARMA INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
Mon, Nov 16 -
EDGAR Online | | • | APPA | | AP PHARMA INC /DE/ Files SEC form 10-Q, Quarterly Report
Mon, Nov 16 -
EDGAR Online | | • | ARDM.OB | | Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Mon, Nov 16 -
Business Wire | | • | ARDM.OB | | ARADIGM CORP Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | ARDM.OB | | New Star Analyst Rankings for ARADIGM CORP
Sun, Nov 8 -
StarMine | | • | ARDM.OB | | ARADIGM CORP Files SEC form 10-Q, Quarterly Report
Fri, Nov 6 -
EDGAR Online | | • | ARDM.OB | | Aradigm Announces Third Quarter 2009 Financial Results
Thu, Nov 5 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
0.04 (1.81%) 
Competitors
